Recall Register

Food, drugs, devices › Tris Pharma Inc.

Drug recall: Morphine Sulfate Oral Solution, 100 mg/ 5 mL (20 mg/mL), packaged in a 1 oz. bottle containing 30 mL with an oral syring

FDA enforcement event 77798 · Class II · initiated 15 Jun 2017 · status Terminated · terminated 8 Nov 2017

DrugVoluntary: Firm initiated1 product recordMonmouth Junction, NJ

FDA enforcement event 77798 is a drug recall by Tris Pharma Inc. of Monmouth Junction, NJ, initiated 15 Jun 2017 and classified Class II, with 1 product record.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 57% of the 343 drug enforcement events initiated in 2017 carry the same class.

Status: Terminated, terminated 8 Nov 2017. Initiation: voluntary: firm initiated. Tris Pharma Inc. has 4 enforcement events on this register, with a median of 3 product records per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Tris Pharma Inc., Monmouth Junction, NJ.

Reason for recall

"Defective container: Oral solution leaking from container."

Distribution

"U.S.A. Nationwide"

Product records

Recall numberProductQuantityClassStatusReport date
D-1126-2017Morphine Sulfate Oral Solution, 100 mg/ 5 mL (20 mg/mL), packaged in a 1 oz. bottle containing 30 mL with an oral syringe, Rx Only, Manufactured by: Tris Pharma, Inc. Monmouth Junction, NJ 08852, NDC 27808-082-0134,824 bottlesClass IITerminated6 Sep 2017

Context

57%of 2017 drug events are Class II343 events that year
1product record in this eventfirm median: 3
4events on this register for the firm

Other enforcement events for Tris Pharma Inc.

InitiatedProduct (first record)TypeClassRecords
11 Jul 2019Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension, (equivalent to 10 mg hydrocodone bitDrugClass II1
15 Jan 2019Infants' Ibuprofen, Concentrated Ibuprofen Oral Suspension, USP, (NSAID), 50 mg per 1.25 mL, Dye Free, Non-staining BerrDrugClass II3
26 Nov 2018infants* IBUPROFEN, Concentrated Ibuprofen Oral Suspension, USP (NSAID), 50 mg per 1.25 mL, Dye-Free Berry Flavor, 0.5 FDrugClass II3

All 4 events for Tris Pharma Inc.

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Defective container: Oral solution leaking from container."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "U.S.A. Nationwide"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 8 Nov 2017. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.